William K, Schmidt, PhD

Dr. William K. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America, and Australia. Bill currently sits on the Scientific or Medical Advisory Boards of 3 biotech companies and one internet medical publishing company.

He is the Parliamentarian and a Past-President of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. Bill has received many awards throughout his career, and received the John J. Bonica award for the development of new analgesics and his sustained contributions to the educational efforts of the Eastern Pain Association in 2014.

He is the co-editor of “Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery” (Marcel Dekker, 2003). Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco. Following his postdoctoral fellowship at Boston University School of Medicine, Dr. Schmidt joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™.

Dr. Schmidt continues to chair the annual Arrowhead Pain Summit (2010-2019) and the Pharmaceutical Roundtable / Innovations in Pain Research for the Eastern Pain Association (2003-2019). In addition to being head of NorthStar Consulting, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs, he is simultaneously President & CEO of Catalina Pharma (Tucson, AZ), part-time Senior VP of Global Clinical Development for Helixmith Inc. (formerly ViroMed, Inc.; Seoul, South Korea), part-time VP of Clinical Development for EicOsis, LLC (Davis, CA), and Chief Medical Officer for Ensysce Biosciences (San Diego, CA).

Bill is considered by many in the field of pain to be an authority on the development of pain pharmaceuticals.